Antibiotics at life's end: key role in treating end-of-life pneumonia?

IF 2.7 Expert review of respiratory medicine Pub Date : 2025-04-01 Epub Date: 2025-03-19 DOI:10.1080/17476348.2025.2479613
Thibaut Fraisse, Alain Putot, Emmanuel Forestier, Gaëtan Gavazzi, Petra Vayne-Bossert, Claire Roubaud-Baudron, Virginie Prendki
{"title":"Antibiotics at life's end: key role in treating end-of-life pneumonia?","authors":"Thibaut Fraisse, Alain Putot, Emmanuel Forestier, Gaëtan Gavazzi, Petra Vayne-Bossert, Claire Roubaud-Baudron, Virginie Prendki","doi":"10.1080/17476348.2025.2479613","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pneumonia is a common occurrence at the end of life (EOL). However, clear definitions and consensual guidelines for managing this condition are lacking. Diagnosing EOL pneumonia and deciding whether to treat it with antibiotics can be challenging.</p><p><strong>Area covered: </strong>This special report provides a narrative review of epidemiological data, diagnostic tools for EOL pneumonia, guidance on antibiotic use, and ethical considerations in this context. Literature from 2000 to 2024 was analyzed using PubMed and Cochrane databases.</p><p><strong>Expert opinion: </strong>At the EOL, respiratory symptoms must be managed to improve patients' quality of life. Bacterial pneumonia can be difficult to diagnose, and the benefits of antibiotics on respiratory symptoms remain uncertain. At an individual level, adverse events may impact EOL quality, while at a population level, overprescribing antibiotics contributes to antimicrobial resistance. A multidisciplinary approach is therefore essential. Treatment goals should be established with the patient or their healthcare representative. If antibiotics are prescribed, they should be initiated for a limited duration with daily reassessments. If the set goals are not achieved or if adverse events occur, antibiotics should be discontinued. Palliative care measures should also be introduced as early as possible.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"279-286"},"PeriodicalIF":2.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert review of respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17476348.2025.2479613","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/19 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Pneumonia is a common occurrence at the end of life (EOL). However, clear definitions and consensual guidelines for managing this condition are lacking. Diagnosing EOL pneumonia and deciding whether to treat it with antibiotics can be challenging.

Area covered: This special report provides a narrative review of epidemiological data, diagnostic tools for EOL pneumonia, guidance on antibiotic use, and ethical considerations in this context. Literature from 2000 to 2024 was analyzed using PubMed and Cochrane databases.

Expert opinion: At the EOL, respiratory symptoms must be managed to improve patients' quality of life. Bacterial pneumonia can be difficult to diagnose, and the benefits of antibiotics on respiratory symptoms remain uncertain. At an individual level, adverse events may impact EOL quality, while at a population level, overprescribing antibiotics contributes to antimicrobial resistance. A multidisciplinary approach is therefore essential. Treatment goals should be established with the patient or their healthcare representative. If antibiotics are prescribed, they should be initiated for a limited duration with daily reassessments. If the set goals are not achieved or if adverse events occur, antibiotics should be discontinued. Palliative care measures should also be introduced as early as possible.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
生命终结时的抗生素:治疗临终肺炎的关键作用?
肺炎是生命末期(EOL)的常见病。然而,缺乏明确的定义和管理这种情况的协商一致的指导方针。诊断EOL肺炎并决定是否用抗生素治疗可能具有挑战性。涉及领域:本特别报告提供流行病学数据、EOL肺炎诊断工具、抗生素使用指南以及这方面的伦理考虑的叙述性回顾。使用PubMed和Cochrane数据库对2000 - 2024年的文献进行分析。专家意见:在EOL,必须控制呼吸症状以改善患者的生活质量。细菌性肺炎可能难以诊断,抗生素对呼吸道症状的益处仍不确定。在个体层面上,不良事件可能会影响EOL质量,而在群体层面上,过量使用抗生素会导致抗菌素耐药性。因此,多学科方法是必不可少的。治疗目标应与患者或其医疗保健代表一起确定。如果开了抗生素,应该在有限的时间内开始使用,每天重新评估。如果没有达到设定的目标或发生不良事件,应停用抗生素。还应尽早采取姑息治疗措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Daytime sleepiness in patients with obstructive sleep apnea and associated comorbidities. Pathological roles of transient receptor potential channels in chronic obstructive pulmonary disease: special focus on cellular mechanisms. Current and future contributions of AI to pulmonary function test interpretation, diagnostic approaches, and predictions of disease progression. From lungs to brain: the neuroimmune impact of respiratory microbiota. Advances in biologic therapies for COPD: precision medicine approaches and implications for small-airway disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1